{"transactions":[{"id":1833483,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-06T22:04:26.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":1440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":9378,"source":{"system":"sec-edgar","filing":"0001209191-23-041650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123041650/doc4.xml","form_type":"4"}},{"id":1924569,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-05T22:07:55.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":1542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7938,"source":{"system":"sec-edgar","filing":"0001209191-23-023435","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123023435/doc4.xml","form_type":"4"}},{"id":2061703,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-01-05T23:26:41.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":6396,"source":{"system":"sec-edgar","filing":"0001209191-23-002062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123002062/doc4.xml","form_type":"4"}},{"id":2141866,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-10-06T01:08:49.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":4989,"source":{"system":"sec-edgar","filing":"0001209191-22-052907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122052907/doc4.xml","form_type":"4"}},{"id":2168741,"issuer":{"id":110807,"kind":"organization","name":"Embark Technology, Inc.","symbol":"EMBK"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":3,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":4,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-09-01T17:38:17.000Z","date":"2022-08-30","kind":"purchase","acquired":true,"shares":10000,"price":9.6388,"value":96388.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price calculated by the broker executing the purchases. These shares were purchased in multiple transactions, and the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects (i) 3,186,007 shares of Class A Common Stock held by Data Collective IV, L.P. (\"DCVC IV\"), (ii) 6,100 shares of Class A Common Stock held by Zachary Bogue and (iii) 20,000 shares of Class A Common Stock held by Matthew Ocko. Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The managing members of DCVC IV GP are Matthew Ocko and Zachary Bogue. Matthew Ocko and Zachary Bogue share voting and dispositive power with respect to the securities held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3212107,"source":{"system":"sec-edgar","filing":"0001827980-22-000081","document":"wf-form4_166206828367843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664972/000182798022000081/wf-form4_166206828367843.xml","form_type":"4"}},{"id":2176683,"issuer":{"id":110807,"kind":"organization","name":"Embark Technology, Inc.","symbol":"EMBK"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":3,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":4,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-22T16:47:07.000Z","date":"2022-08-18","kind":"purchase","acquired":true,"shares":10000,"price":11.6383,"value":116383.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.51 to $11.68. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects (i) 3,186,007 shares of Class A Common Stock held by Data Collective IV, L.P. (\"DCVC IV\"), (ii) 6,100 shares of Class A Common Stock held by Zachary Bogue and (iii) 10,000 shares of Class A Common Stock held by Matthew Ocko. Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The managing members of DCVC IV GP are Matthew Ocko and Zachary Bogue. Matthew Ocko and Zachary Bogue share voting and dispositive power with respect to the securities held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3202107,"source":{"system":"sec-edgar","filing":"0001827980-22-000078","document":"wf-form4_166120120791894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664972/000182798022000078/wf-form4_166120120791894.xml","form_type":"4"}},{"id":2179084,"issuer":{"id":110807,"kind":"organization","name":"Embark Technology, Inc.","symbol":"EMBK"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":3,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":4,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-18T21:06:06.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":122000,"price":0.8373,"value":102150.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.82 to $0.8594. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the amount of shares beneficially held following a 20-for-1 stock split effected by the Issuer on August 16, 2022, which was exempt from reporting pursuant to Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects (i) 3,186,007 shares of Class A Common Stock held by Data Collective IV, L.P. (\"DCVC IV\") and (ii) 6,100 shares of Class A Common Stock held by Zachary Bogue. Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The managing members of DCVC IV GP are Matthew Ocko and Zachary Bogue. Matthew Ocko and Zachary Bogue share voting and dispositive power with respect to the securities held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3192107,"source":{"system":"sec-edgar","filing":"0001827980-22-000076","document":"wf-form4_166087115119894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664972/000182798022000076/wf-form4_166087115119894.xml","form_type":"4"}},{"id":2211331,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-07-06T21:45:19.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":1260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":4012,"source":{"system":"sec-edgar","filing":"0001209191-22-041270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122041270/doc4.xml","form_type":"4"}},{"id":2303476,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-04-05T23:26:49.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":1382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":2752,"source":{"system":"sec-edgar","filing":"0001209191-22-023323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122023323/doc4.xml","form_type":"4"}},{"id":2442780,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-06T01:38:07.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":1370,"source":{"system":"sec-edgar","filing":"0001209191-22-002045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122002045/doc4.xml","form_type":"4"}},{"id":2547966,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-10-06T00:29:59.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":781,"source":{"system":"sec-edgar","filing":"0001209191-21-059741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121059741/doc4.xml","form_type":"4"}},{"id":2640468,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-06T21:00:20.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":295,"source":{"system":"sec-edgar","filing":"0001209191-21-045549","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121045549/doc4.xml","form_type":"4"}},{"id":2658202,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":2,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":3,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":4,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":5,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":6,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":7,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2021-06-22T22:13:35.000Z","date":"2021-06-18","kind":"other","acquired":true,"shares":73892,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by DCVC Bio GP.  JNK and ZNM are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio GP. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":73892,"source":{"system":"sec-edgar","filing":"0001209191-21-042496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919121042496/doc4.xml","form_type":"4"}},{"id":2658201,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":2,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":3,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":4,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":5,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":6,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":7,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2021-06-22T22:13:35.000Z","date":"2021-06-18","kind":"other","acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":24105761,"source":{"system":"sec-edgar","filing":"0001209191-21-042496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919121042496/doc4.xml","form_type":"4"}},{"id":2741550,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3726963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3726963},"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741549,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":730353,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":730353},"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741548,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1095529,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1095529},"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741547,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3220788,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3220788},"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741546,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1073595,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1073595},"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741545,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3771996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3771996},"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741544,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3726963,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741543,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741542,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3726963,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741541,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3951141,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741540,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741539,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3951141,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741538,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":5941120,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741537,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2741536,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":111559,"kind":"person","name":"Bogue Zachary","position":1,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:28:22.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":5941120,"source":{"system":"sec-edgar","filing":"0001209191-21-028016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028016/doc4.xml","form_type":"4"}},{"id":2939104,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"price":0,"reported_value":500000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Shares","underlying_shares":29411},"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939103,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A2 Preferred Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":802371,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":8023710},"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939102,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A1 Preferred Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":2105264,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":21052640},"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939101,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":29411,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":29105761,"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939100,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":29076350,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":29076350,"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}}]}